Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
To compare the event-free survival at 2 years of CPX-351 vs. conventional care regimens
before allogeneic blood cell transplantation as first line treatment in patients with higher
risk MDS and oligoblastic AML.